阿摩線上測驗
38.胰臟癌（pancreatic ductal adenocarcinoma）逐年增加，其藥物治療學近年來也有相當的進展。下列有關胰臟癌
藥物治療進展的敘述，何者最不恰當？
(A)局部胰臟癌手術後，應進行輔助性化學治療半年
(B)胰臟癌術後輔助性化學治療，已有第三期臨床試驗證實gemcitabine + capecitabine優於gemcitabine
(C)晚期及轉移的胰臟癌應進行全身性化學治療，目前的研究顯示：組合式化學化療（combination chemotherapy）並未優於gemcitabine單一治療
(D)針對gemcitabine治療失敗的晚期或轉移胰臟癌病患，liposomal irinotecan + 5-fluorouracil + leucovorin因可改 善病患的整體存活期，已被美國衛生主管機關（FDA）核准通過
答案：登入後查看
統計： A(13), B(79), C(565), D(72), E(0) #2866456
統計： A(13), B(79), C(565), D(72), E(0) #2866456
詳解 (共 2 筆)
chin8941
#6042921
(B)
ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-FU/folinic acid in patients with resected pancreatic cancer.
ESPAC-4 trial showed that adjuvant gemcitabine and capecitabine is the new standard of care in patients with resected pancreatic cancer than gemcitabine monotherapy.
ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-FU/folinic acid in patients with resected pancreatic cancer.
ESPAC-4 trial showed that adjuvant gemcitabine and capecitabine is the new standard of care in patients with resected pancreatic cancer than gemcitabine monotherapy.
(D)
liposomal irinotecan (nal-IRI) + 5-fluorouracil + leucovorin (5-FU/LV) is approved for patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy, based on NAPOLI-1 trial.
4
0
到底在考三小
#6437800
考邏輯:
CD二選一，BD都正確的話C就錯->答C
ㅤㅤ
ㅤㅤ
補字數補字數補字數補字數補字數補字數補字數補字數補字數補字數補字數補字數
2
0